GHK-Cu vs Melanotan 2
GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine, an endogenous human plasma tripeptide studied for collagen synthesis, extracellular matrix remodelling and wound repair. Melanotan II is a synthetic, non-selective analogue of alpha-melanocyte-stimulating hormone that acts across melanocortin receptors to increase eumelanin synthesis, and it is sold illegally for tanning. The two are set side by side in vendor material because both are injected peptides marketed for skin, but they share no mechanism, no target and no indication. No study has administered both, compared them, or tested whether one affects the other. The two publications that engage both are recent reviews that group them by market category rather than by biology: one places GHK-Cu among regenerative peptides and Melanotan II among melanocortin analogues, and the other lists them together in a single aesthetics, skin and tanning row of a table of unregulated consumer peptides. Everything else here is indirect.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No study has administered GHK-Cu and Melanotan II in the same experiment, in any model, and none has compared them on any endpoint. Searches of PubMed and Europe PMC returned two publications that engage both, and neither dosed anything. A 2026 review of therapeutic peptides in aesthetic, metabolic and endocrine conditions covered GHK-Cu among regenerative and wound-healing peptides supplied in topical dermatological formulations, and covered Melanotan II among melanocortin analogues alongside afamelanotide and bremelanotide that act at MC1R through MC5R. A 2026 narrative review of unregulated peptide use grouped the two in one row of its claim table, headed aesthetics, skin and tanning, and identified the shared concern as cosmetic normalisation of systemic or injectable products of uncertain identity, purity, potency and sterility. Both papers therefore link the two compounds by how they are marketed and sold rather than by anything either does in tissue, and the biological literatures behind them do not overlap.
The 2 publications that cover both
- 01Review2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Renke G, Chinellato L · International Journal of Molecular Sciences · narrative review of 106 articles, prioritising systematic reviews, meta-analyses and randomised controlled trials
GHK-Cu was covered among peptides that promote healing and tissue regeneration and modulate inflammation, alongside BPC-157, thymosin beta-4 and thymosin alpha-1, and was noted as available in topical and transdermal dermatological formulations for local action. Melanotan II was covered in a separate melanocortin section with afamelanotide and bremelanotide, described as analogues of alpha-MSH and ACTH acting at receptors MC1R to MC5R and therefore affecting pigmentation, libido, appetite and mood. Neither compound was administered and the review drew no comparison between them.
- 02Review2026
Unregulated Peptide Use in the Age of Biohacking: Digital Promotion, Gray-Market Access, and Emerging Public Health Risks
Hailu KT, et al. · Cureus · narrative review of digital promotion, gray-market access and pharmacovigilance gaps for unregulated peptides, with searches covering named compounds including GHK-Cu and melanotan
The review's table of digital claim categories placed GHK-Cu and melanotan-type peptides together in one row headed aesthetics, skin and tanning, giving the associated public health concern as cosmetic normalisation of systemic or injectable products. GHK-Cu was additionally assigned to an experimental and wellness tier whose stated risk is that online visibility exceeds human evidence and safety characterisation, while melanotan-type peptides were described as circulating through online forums and regulatory warnings. Neither was administered.
Reported safety finding. Both compounds were characterised as consumer products of uncertain identity, purity, potency and sterility, sold outside clinical supervision and outside any pharmacovigilance system.
Side by side.
| GHK-Cu | Melanotan 2 | |
|---|---|---|
| Evidence maturity | Early clinical | Approved drug |
| Studies cited here | 15 | 20 |
| Published 2023 or later | 10 | 12 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | The copper(II) complex of glycyl-L-histidyl-L-lysine, a three-residue peptide present in human plasma that binds copper with high affinity. The GHK triplet also occurs within the alpha-2(I) chain of type I collagen, which is the proposed endogenous source. | A synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, non-selective across melanocortin receptors. It is not an endogenous human peptide, and it differs from the MC1R-selective analogue afamelanotide that carries a marketing authorisation. |
| Mechanism as described in the literature | Stimulation of fibroblast collagen and glycosaminoglycan synthesis at picomolar to nanomolar concentrations, plus reported modulation of extracellular-matrix, antioxidant and inflammatory gene programmes. A 2024 study identified peroxiredoxin 6 as a direct binding target in a mouse lung fibrosis model. | Agonism at melanocortin receptors, increasing eumelanin synthesis in melanocytes through MC1R. Because the peptide is not receptor-selective, it also engages MC3R, MC4R and MC5R, which is the published explanation for its effects on appetite, sexual function and other systems beyond pigmentation. |
| Size and composition of the evidence base | Fifteen studies in this library: six human clinical, four in vitro, two animal in vivo, two reviews and one systematic review. The 2026 PRISMA systematic review searched from database inception to March 2026 and identified only twenty eligible studies of the peptide as a standalone aesthetic intervention, eighteen preclinical and two randomised controlled trials. | Twenty studies in this library, but they are not all about this compound: seven human clinical, eight case reports, three reviews and two systematic reviews. The human trials tested the approved analogues afamelanotide and dersimelagon, not Melanotan II, whose own human record is the case-report series. |
| What the human data actually cover | Topical use in wound and post-procedure settings, with mixed results. The largest randomised trial, in venous stasis ulcers, found no difference from inert vehicle while silver sulfadiazine outperformed both. A randomised trial on CO2 laser-resurfaced skin found no significant difference on objective endpoints. A placebo-controlled hair-growth trial of a 5-aminolevulinic acid and GHK complex reported increased hair count. | Nothing on Melanotan II itself. The randomised evidence concerns afamelanotide in erythropoietic protoporphyria and in vitiligo with narrowband UV-B, plus a phase 2 trial of the oral MC1R agonist dersimelagon. Because Melanotan II is non-selective across melanocortin receptors, those trial data cannot be used to infer its safety. |
| Best-characterised finding | Stimulation of collagen synthesis in cultured fibroblasts, first reported in 1988 with a dose-response beginning between 10^-12 and 10^-11 M and peaking at 10^-9 M, independent of any change in cell number. | Induction of skin pigmentation through melanocortin receptor agonism, which is not disputed. What is disputed is whether the resulting tan is protective, and whether the exposure carries melanocytic risk; the pigmentation effect itself is the reason the compound is sold. |
| Safety signals reported | Few in the published record. The controlled trials that found no benefit also reported no distinctive safety concern, and a 2026 hydrogel study containing an NE1 peptide carrying the GHK sequence reported the composition as safe on dermatological testing. Systemic exposure from cosmetic vehicles is not well characterised. | Extensive and consistent. Published case reports document eruptive and dysplastic melanocytic naevi, cutaneous melanoma and melanoma in situ, oral mucosal malignant melanoma after nasal spray use, mucosal hyperpigmentation, depigmentation and pyoderma gangrenosum. Whether melanotan exposure causes melanoma is unresolved, because the reported cases are confounded by concurrent ultraviolet and sunbed exposure. |
| Regulatory status | Used as a cosmetic ingredient under the INCI name copper tripeptide-1 rather than as a medicine. It has no marketing authorisation for any therapeutic indication, and a 2026 systematic review noted the absence of standardised clinical guidelines despite growing use in aesthetic practice. | Unlicensed everywhere and sold illegally. No completed randomised controlled trial exists for any indication, no pharmacovigilance system covers it, and the purity, dose and sterility of illicitly supplied product are uncharacterised. The related selective analogue afamelanotide is separately approved and subject to regulator-mandated post-authorisation safety studies. |
| Basis of most marketing claims | Extrapolation from in vitro collagen and gene-expression data to topical cosmetic outcomes that the controlled trials did not confirm, with skin permeation from cosmetic vehicles poorly characterised and no human dose-response for a topical anti-wrinkle effect established. | Extrapolation from the approved MC1R-selective analogue and from the undisputed pigmentation mechanism to claims of safe tanning and photoprotection, in a compound that has never completed a safety or efficacy programme and whose case-report literature runs the other way. |
And what it does not.
These two compounds are compared because they are sold in the same place, not because the literature relates them. No experiment has used both, and the two publications that name both group them by consumer market category rather than by biology. On the separate evidence: GHK-Cu has decades of mechanistic in vitro work and a small, mixed set of controlled human trials, two of the largest of which found no advantage over comparator or placebo, and a 2026 systematic review that located only two randomised trials of it as a standalone aesthetic intervention. Melanotan II has no completed trial of any kind; its randomised evidence belongs to different, receptor-selective molecules, and its own human literature consists of case reports of eruptive naevi, melanoma, mucosal melanoma, pigmentary change and inflammatory dermatoses, all collected without a pharmacovigilance system behind them. The honest summary is that one compound is under-evidenced and the other is unstudied but repeatedly implicated in harm reports, and that no published work supports using them as alternatives to each other.
Common questions.
- Do GHK-Cu and Melanotan 2 act on the same pathway in skin?
No. GHK-Cu is a copper-binding tripeptide associated with fibroblast collagen and glycosaminoglycan synthesis and with extracellular matrix remodelling, and a 2024 animal study identified peroxiredoxin 6 as a direct binding target. Melanotan II is a melanocortin receptor agonist that increases eumelanin production in melanocytes and, because it is not receptor-selective, also engages receptors involved in appetite and sexual function. The two engage different cell types, different receptors and different downstream biology, and nothing published connects them mechanistically.
- Why do the two publications that name both compounds not compare them?
Because both are reviews of a market rather than experiments. A 2026 review of therapeutic peptides in aesthetic, metabolic and endocrine conditions covered them in separate sections, regenerative peptides for one and melanocortin analogues for the other. A 2026 review of unregulated peptide use listed them in the same row of a table of digital claim categories, headed aesthetics, skin and tanning, because both are promoted online for cosmetic goals. Neither paper administered either compound or measured any comparative endpoint.
- Does the afamelanotide trial evidence apply to Melanotan 2?
It does not, and the research entry for Melanotan 2 in this library states the reason. Afamelanotide is a largely MC1R-directed analogue approved for erythropoietic protoporphyria on the basis of randomised placebo-controlled trials and supported by regulator-mandated post-authorisation safety studies. Melanotan II is non-selective across melanocortin receptors, so its systemic effects differ, and no completed randomised trial of it exists for any indication. Transferring the approved analogue's safety record to the unlicensed one is not supported.
- Which of the two has stronger controlled human evidence?
GHK-Cu, although the margin is smaller than it appears and the direction of the results is not favourable. Randomised controlled trials of topical copper tripeptide exist in venous stasis ulcers and on CO2 laser-resurfaced skin, and both found no significant benefit on their objective endpoints. A placebo-controlled hair-growth trial of a combined 5-aminolevulinic acid and GHK preparation did report increased hair count. Melanotan II has no controlled human trial at all, so the comparison is between weak evidence and none.
- What does the case-report literature on Melanotan 2 establish?
It establishes a pattern of reported harms, not causation. Independent reports from several countries document eruptive and dysplastic melanocytic naevi, cutaneous melanoma and melanoma in situ, oral mucosal malignant melanoma following nasal spray use, mucosal hyperpigmentation, depigmentation and pyoderma gangrenosum. The melanoma cases are consistently confounded by concurrent ultraviolet and sunbed exposure, and no controlled epidemiological study exists. Because supply is unregulated, the true incidence of any of these events cannot be measured.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.